...
首页> 外文期刊>Cytogenetic and genome research >Isodicentric Philadelphia Chromosome: A Rare Chromosomal Aberration in Imatinib-Resistant Chronic Myelogenous Leukemia Patients - Case Report with Review of the Literature
【24h】

Isodicentric Philadelphia Chromosome: A Rare Chromosomal Aberration in Imatinib-Resistant Chronic Myelogenous Leukemia Patients - Case Report with Review of the Literature

机译:等中心性的费城染色体:伊马替尼耐药的慢性粒细胞性白血病患者的罕见染色体畸变-文献综述

获取原文
获取原文并翻译 | 示例
           

摘要

The BCR-ABL1 fusion gene derived from the Philadelphia chromosome, resulting from a classical translocation event t(9;22)(q34.13;q11.23), is responsible for the pathogenesis of chronic myeloid leukemia (CML) in more than 90% of the patients. The isoderivative chromosome 22, ider(22), and relative amplification or duplication of the BCR-ABL1 gene have been considered as one of the major reasons associated with the resistance to chemotherapy with imatinib mesylate, but the data remain unclear. GTG-banding together with FISH were performed to identify the presence of the ider(22) chromosome. Reverse transcription-polymerase chain reaction (RT-PCR) for the detection of BCR-ABL1 fusion transcripts and BCR-ABL1 kinase domain mutation analysis were carried out in this study. Conventional and molecular cytogenetic analysis on metaphase chromosomes confirmed the presence of ider(22) chromosomes in both patients. Molecular characterization revealed the presence of a 210-kDa BCR-ABL1 type b3a2 and lack of mutations at the kinase domain region on the fusion product in both patients. The occurrence of the ider(22) chromosome could be considered as an important marker correlated with the aggressive progression of CML as well as the emergence of drug-resistant cell clones. (C) 2017 S. Karger AG, Basel
机译:来自费城染色体的BCR-ABL1融合基因是由经典易位事件t(9; 22)(q34.13; q11.23)引起的,它与90年代以来的慢性粒细胞白血病(CML)的发病机理有关%的患者。等变性22号染色体,ider(22)和BCR-ABL1基因的相对扩增或重复被认为是与甲磺酸伊马替尼耐药性相关的主要原因之一,但数据尚不清楚。 GTG带和FISH一起进行以鉴定ider(22)染色体的存在。在这项研究中进行了逆转录-聚合酶链反应(RT-PCR)的BCR-ABL1融合转录本的检测和BCR-ABL1激酶域突变分析。对中期染色体的常规和分子细胞遗传学分析证实了两名患者均存在ider(22)染色体。分子表征显示在两名患者中均存在210 kDa BCR-ABL1型b3a2,并且在融合产物上的激酶结构域区域缺少突变。 ider(22)染色体的出现可以被视为与CML的侵袭性进展以及耐药细胞克隆的出现有关的重要标志。 (C)2017巴塞尔S.Karger AG

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号